Thank you, Chair. I'll be splitting my time with Ms. Sidhu.
We've heard a lot of evidence certainly around rare diseases where there are trial drugs, and once they get approved, the price goes through the roof, or when another drug becomes an approved drug, the previous drugs that might be cheaper end up not being available anymore.
We're also hearing about the need for people on the special access program to reapply for coverage on a three-month basis.
I'll open it up to all of you to answer the questions, if you can.
What can the department do to streamline and facilitate access to these drugs for rare disorders?